Perez-Ruixo JJ - Search Results

1

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.

Perez-Ruixo JJ, Zannikos P, Ozdemir V, Franc MA, Francke S, Piotrovsky V. Perez-Ruixo JJ, et al. Cancer Chemother Pharmacol. 2006 Nov;58(5):681-91. doi: 10.1007/s00280-006-0215-8. Epub 2006 Mar 17. Cancer Chemother Pharmacol. 2006. PMID: 16544144 Clinical Trial.

2

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.

Perez-Ruixo JJ, Piotrovskij V, Zhang S, Hayes S, De Porre P, Zannikos P. Perez-Ruixo JJ, et al. Br J Clin Pharmacol. 2006 Jul;62(1):81-96. doi: 10.1111/j.1365-2125.2006.02615.x. Br J Clin Pharmacol. 2006. PMID: 16842381 Free PMC article.

3

Exposure-toxicity relationships for tipifarnib in cancer patients.

Perez-Ruixo JJ, Chen W, Zhang S, Hayes S, Chow A. Perez-Ruixo JJ, et al. Br J Clin Pharmacol. 2007 Aug;64(2):219-32. doi: 10.1111/j.1365-2125.2007.02883.x. Epub 2007 Mar 22. Br J Clin Pharmacol. 2007. PMID: 17378913 Free PMC article. Clinical Trial.

4

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P. Hing J, et al. Clin Pharmacol Ther. 2008 Jan;83(1):130-43. doi: 10.1038/sj.clpt.6100259. Epub 2007 Jun 27. Clin Pharmacol Ther. 2008. PMID: 17597713

5

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

Perez-Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS. Perez-Ruixo JJ, et al. Clin Pharmacokinet. 2007;46(10):867-84. doi: 10.2165/00003088-200746100-00005. Clin Pharmacokinet. 2007. PMID: 17854236

6

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.

Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Soto-Matos A, Izquierdo MA, Perez-Ruixo JJ. Fetterly GJ, et al. Cancer Chemother Pharmacol. 2008 Jun;62(1):135-47. doi: 10.1007/s00280-007-0583-8. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922277

7

Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.

Nalda-Molina R, Valenzuela B, Ramon-Lopez A, Miguel-Lillo B, Soto-Matos A, Perez-Ruixo JJ. Nalda-Molina R, et al. Cancer Chemother Pharmacol. 2009 Jun;64(1):97-108. doi: 10.1007/s00280-008-0841-4. Epub 2008 Oct 22. Cancer Chemother Pharmacol. 2009. PMID: 18941750

8

Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.

Ortega I, Perez-Ruixo JJ, Stuyckens K, Piotrovsky V, Vermeulen A. Ortega I, et al. J Clin Pharmacol. 2010 Mar;50(3):293-310. doi: 10.1177/0091270009346057. Epub 2010 Jan 7. J Clin Pharmacol. 2010. PMID: 20056804

9

Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.

Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ. Pérez-Ruixo C, et al. Cancer Chemother Pharmacol. 2012 Jan;69(1):15-24. doi: 10.1007/s00280-011-1644-6. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590449 Clinical Trial.

10

Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.

Pérez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farré-Alegre J, Pérez-Ruixo JJ. Pérez-Ruixo C, et al. Cancer Chemother Pharmacol. 2013 Mar;71(3):693-704. doi: 10.1007/s00280-012-2060-2. Epub 2012 Dec 30. Cancer Chemother Pharmacol. 2013. PMID: 23274396

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters